Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
LBA2 Sintilimab plus bevacizumab biosimilar vs sorafenib as first-line treatment for advanced hepatocellular carcinoma (ORIENT-32)2
PaperCitations, authors & open-access status
LBA2 Sintilimab plus bevacizumab biosimilar vs sorafenib as first-line treatment for advanced hepatocellular carcinoma (ORIENT-32)2 is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 32 citations, 2020 year and closed oa status.
32
Citations
2020
Year
closed
OA Status